Patient-friendly dosage forms: the potential of galenIQ™ in formulations of lozenges

galenIQ™ is a key ingredient that transforms the taste, texture, and effectiveness of medicated lozenges. It emerges as a secret support in texture and taste. Its exceptional binding properties contribute to the formation of robust lozenges that dissolve slowly, releasing medication effectively and ensuring a sustained soothing experience. The result is a medicated lozenge that not only delivers the intended therapeutic benefits but also appeals to the palate.

galenIQ™ 720: Ideal for compressed lozenge tablets

Compressed lozenge tablets, also known as buccal tablets, remain in the mouth for several minutes. This makes taste and mouthfeel critical for patient acceptance. galenIQ™ 720 is specifically designed to support this application. It enables reliable tableting and precise dosing, while helping to mask the unpleasant taste of many active ingredients.

When a tablet may stay in the mouth for two to three minutes, palatability becomes essential. Using galenIQ™ in the formulation can therefore make a real difference for both producers and end users. If you want to get the formulation right the first time, galenIQ™ is a reliable choice.

Key advantages:

• Easy to tablet
• Excellent palatability

Discover even more advantages: Patient-friendly chewable tablets

Chewable tablets are widely used for patient-centric dosage forms, particularly for paediatric, geriatric or dysphagic patients who may struggle with conventional tablets. For these formats, taste, mouthfeel and disintegration behaviour are key factors influencing patient acceptance.

In our short animated video, we explain how galenIQ™ can support the development of chewable tablets with a pleasant taste, smooth mouthfeel and reliable performance during tableting: galenIQ™ – the sweet pharmaceutical excipient.

Check out the animated video.

From our podcast: Formulation insights in practice

In our latest Excipient Talk podcast episode, recorded live at CPhI 2025 in Milan with Sales Manager Larry Walsh, Jr. and Michael Black, we explore a practical formulation example using galenIQ™.

Larry will showcase a chewable simethicone tablet developed by Azelis US using galenIQ™ 721. The discussion highlights how this agglomerated grade supports the development of patient-friendly chewable dosage forms, combining good compressibility with pleasant taste.

Listen to the episode to discover how galenIQ™ can support innovative formulations for chewables and other oral dosage forms.

Order your sample of galenIQ™: